Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 6/20 | 0.66 |
| ▸ | PLA2G7 | Q13093 | 11/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6151338 | 0.80 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL6151642 | 0.78 | SLC6A4 (0.77) | SLC6A4PTGS2SLC6A2SLC6A3 | |
| SCHEMBL6863684 | 0.77 | ALDH1A1 (0.60) | PLA2G7PGR | |
| SCHEMBL6151699 | 0.77 | SLC6A4 (0.46) | SLC6A4PLA2G7PTGS2SLC6A2SLC6A3 | |
| SCHEMBL6152088 | 0.75 | KDM4E (0.55) | SLC6A4SLC6A2SLC6A3CYP3A4 | |
| SCHEMBL13065706 | 0.73 | SLC22A12 (0.43) | PGR | |
| SCHEMBL6153036 | 0.72 | VCAM1 (0.47) | PLA2G7 | |
| SCHEMBL20510870 | 0.72 | CYP19A1 (0.50) | SLC6A4 | |
| SCHEMBL30360758 | 0.72 | CYP19A1 (0.50) | SLC6A4 | |
| SCHEMBL6152010 | 0.72 | SLC6A4 (0.47) | SLC6A4PLA2G7PTGS2SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1268396-B1 | DIPHENYL ETHER COMPOUNDS USEFUL IN THERAPY | PFIZER LTD (GB) | 2005-07-20 | — | — | EP | disclosed |
| US-6448293-B1 | TREATMENT OR PREVENTION OF A DISORDER IN WHICH THE REGULATION OF MONOAMINE TRANSPORTER FUNCTION IS IMPLICATED, SUCH AS PREMATURE EJACULATION. | PFIZER INC. | 2002-09-10 | — | — | US | disclosed |
| US-20020052395-A1 | Diphenyl ether compounds useful in therapy | ANDREWS MARK DAVID (GB) | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052395-A1 | Diphenyl ether compounds useful in therapy | CBR1, OGFR, CBR3 | SLC6A4 2002/4885PLA2G7 4077/4885PTGS2 2397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.